Demonstration of direct bioanalysis of drugs in plasma using nanoelectrospray infusion from a silicon chip coupled with tandem mass spectrometry

被引:96
作者
Dethy, JM [1 ]
Ackermann, BL
Delatour, C
Henion, JD
Schultz, GA
机构
[1] Eli Lilly & Co, Lilly Dev Ctr SA, B-1348 Mont St Guibert, Belgium
[2] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Advion BioSci Inc, Ithaca, NY 14850 USA
关键词
D O I
10.1021/ac0260692
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Quantitative bioanalysis by direct nanoelectrospray infusion coupled to tandem mass spectrometry has been achieved using an automated liquid sampler integrated with an array of microfabricated electrospray nozzles allowing rapid, serial sample introduction (1 min/ sample). Standard curves prepared in human plasma for verapamil (r(2) = 0.999) and its metabolite norverapamil (r(2) = 0.998) were linear over a range of 2.5-500 ng/ mL. Based on the observed precision and accuracy, a lower limit of quantitation of 5 ng/mL was assigned for both analytes. Sample preparation consisted of protein precipitation with an organic solvent containing the structural analogue gallopamil as an internal standard. Protein precipitation was selected both to maximize throughput and to test the robustness of direct nanoelectrospray infusion. Aliquots of supernatant (10 muL) were transferred to the back plane of the chip using disposable, conductive pipet tips for direct infusion at a flow rate of 300 nL/min. Electrospray ionization occurred from the etched nozzles (30-mum o.d.) on the front of the chip, initiated by a voltage applied to the liquid through the pipet tip. The chip was positioned near the API sampling orifice of a triple quadrupole mass spectrometer, which was operated in selected reaction monitoring mode. Results are presented that document the complete elimination of system carry-over, attributed to lack of a redundant fluid path. This technology offers potential advantages for MS-based screening applications in drug discovery by reducing the time for methods development and sample analysis.
引用
收藏
页码:805 / 811
页数:7
相关论文
共 35 条
  • [1] Ackermann Bradley L., 2002, Current Topics in Medicinal Chemistry, V2, P53, DOI 10.2174/1568026023394605
  • [2] Ayrton J, 1997, RAPID COMMUN MASS SP, V11, P1953, DOI 10.1002/(SICI)1097-0231(199712)11:18<1953::AID-RCM102>3.0.CO
  • [3] 2-Z
  • [4] BEVERLY MB, UNPUB RAPID COMMUN M
  • [5] An integrated fluorescence detection system in poly(dimethylsiloxane) for microfluidic applications
    Chabinyc, ML
    Chiu, DT
    McDonald, JC
    Stroock, AD
    Christian, JF
    Karger, AM
    Whitesides, GM
    [J]. ANALYTICAL CHEMISTRY, 2001, 73 (18) : 4491 - 4498
  • [6] Chen S, 2001, RAPID COMMUN MASS SP, V15, P159, DOI 10.1002/1097-0231(20010130)15:2<159::AID-RCM210>3.0.CO
  • [7] 2-W
  • [8] Multiport flow-control system for lab-on-a-chip microfluidic devices
    Chien, RL
    Parce, JW
    [J]. FRESENIUS JOURNAL OF ANALYTICAL CHEMISTRY, 2001, 371 (02): : 106 - 111
  • [9] A predictive model for matrix and analyte effects in electrospray ionization of singly-charged ionic analytes
    Enke, CG
    [J]. ANALYTICAL CHEMISTRY, 1997, 69 (23) : 4885 - 4893
  • [10] *FDA GUID IND CTR, BIOPH BIOAN METH VAL